REFRACTORY MYELODYSPLASTIC SYNDROME

This study is testing a new, more intensive treatment plan for adults with aggressive blood cancers that are likely to return. The plan involves a combination of chemotherapy drugs and radiation, followed by a stem cell transplant from a donor. The goal is to see if this stronger…

This is a first-in-human study to find a safe dose and understand the side effects of an experimental drug called TAK-243. It is for adults with acute myeloid leukemia or myelodysplastic syndromes that have returned or not responded to prior treatments. The drug is given by IV an…

This study is testing a new approach to stem cell transplant for adults with aggressive blood cancers that have returned or not responded to treatment. The goal is to find the safest dose of radiation when combined with strong chemotherapy before the transplant, aiming to better …

This study is testing whether a medication called canakinumab, given as a monthly injection, can help control certain low-risk blood and bone marrow disorders. It aims to see if the treatment improves blood counts, reduces the need for blood transfusions, and is safe for patients…

This early-stage study is testing whether adding metal-detoxifying drugs to standard chemotherapy can help control acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Researchers want to see if lowering metal levels in the blood and bone marrow improves treatment res…

This study is testing a combination of two drugs, CPX-351 and quizartinib, to see if they can help control acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The main goals are to find the safest and most effective dose and to see how well the treatment wo…

This early-stage trial is testing a new combination of three drugs for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or not responded to other treatments. The goal is to find the safest and most effective dose by combining an immunot…

This is a first-in-human study to find a safe dose of a new drug called cirtuvivint for patients with advanced forms of blood cancer. The trial will test cirtuvivint by itself in patients whose cancer has returned or resisted treatment, and also test it combined with an existing …

This study is testing an oral drug called ONC201, alone or with another drug, for adults with advanced blood cancers that have returned or are not responding to standard treatments. The main goals are to find the safest and most effective dose and to see if the treatment can help…

This early-stage study is testing a new oral medication called Q702 for patients with advanced blood cancers and rare immune cell disorders that have not responded to standard treatments. The main goals are to find the safest dose and see what side effects occur. Researchers hope…

This early-stage trial is testing a new cell therapy for children and adults whose leukemia has come back or persists after a donor stem cell transplant. Doctors take immune cells (T cells) from the original donor, genetically modify them to better recognize and attack the patien…